Vor Biopharma (VOR) Non-Current Assets (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Non-Current Assets of $6.0 million for Q1 2026, down 86.58% year-over-year from $44.5 million in Q1 2025, and down 0.88% quarter-over-quarter from $6.0 million in Q4 2025.
Vor Biopharma (VOR) Non-Current Assets (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Non-Current Assets for 7 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 86.58% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $16.2 million (down 91.52% YoY), while the FY2025 annual figure was $6.0 million, down 87.02% from the prior year.
- Non-Current Assets slipped to $6.0 million in Q1 2026 per VOR's latest filing, from $6.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $65.8 million in Q2 2022 and bottomed at $444000.0 in Q2 2025.
- Historically, Non-Current Assets has averaged $43.2 million across 5 years, with a median of $51.3 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 154.16% — and 2025, when it plunged 99.14%.
- Vor Biopharma's Non-Current Assets stood at $62.4 million in 2022, then decreased by 8.16% to $57.3 million in 2023, then dropped by 19.08% to $46.4 million in 2024, then sank by 87.02% to $6.0 million in 2025, then declined by 0.88% to $6.0 million in 2026.
- Business Quant data shows VOR's Non-Current Assets at $6.0 million in Q1 2026, $6.0 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | 5.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.95 Mn |
| Mar 31, 2026 | 5.97 Mn |
| Dec 31, 2025 | 6.02 Mn |
| Sep 30, 2025 | 3.75 Mn |
| Jun 30, 2025 | 444,000.00 |
| Mar 31, 2025 | 44.47 Mn |
| Dec 31, 2024 | 46.38 Mn |
| Sep 30, 2024 | 48.70 Mn |
| Jun 30, 2024 | 51.33 Mn |
| Mar 31, 2024 | 55.21 Mn |
| Dec 31, 2023 | 57.32 Mn |
| Sep 30, 2023 | 58.59 Mn |
| Jun 30, 2023 | 59.59 Mn |
| Mar 31, 2023 | 60.64 Mn |
| Dec 31, 2022 | 62.42 Mn |
| Sep 30, 2022 | 63.64 Mn |
| Jun 30, 2022 | 65.77 Mn |
| Mar 31, 2022 | 43.97 Mn |
| Dec 31, 2021 | 28.19 Mn |
| Sep 30, 2021 | 26.56 Mn |